VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

Zostavax
Vaccine Information
  • Vaccine Name: Zostavax
  • Target Pathogen: Varicella-zoster virus
  • Target Disease: chickenpox / shingles
  • Product Name: Zoster Vaccine, Live, (Oka/Merck)
  • Tradename: Zostavax
  • Manufacturer: Merck & Co., Inc.
  • Vaccine Ontology ID: VO_0000124
  • CDC CVX code: 121
  • Type: Live, attenuated vaccine
  • Status: Licensed
  • Location Licensed: USA (License #0002)
  • Host Species for Licensed Use: Human
  • Antigen: live, attenuated varicella-zoster virus (Oka/Merck)
  • Preparation: ZOSTAVAX is a lyophilized preparation of live, attenuated varicella-zoster virus (Oka/Merck) to be reconstituted with sterile diluent to give a single dose suspension with a minimum of 19,400 PFU (plaque forming units) when stored at room temperature for up to 30 minutes (FDA: Zostavax).
  • Storage: ZOSTAVAX SHOULD BE stored FROZEN at an average temperature of -15°C (+5°F) or colder.
  • Approved Age for Licensed Use: 60 years and older
  • Contraindication: Should not be administered to anyone with known anaphylactic/anaphylactoid reaction to gelatin, neomycin, or any other component of the vaccine. The vaccine should also not be administered to women of child-bearing age or to pregnant women (FDA: Zostavax).
  • Description: Indication: Prevention of herpes zoster (shingles) in individuals 60 years of age and older when administered as a single-dose (FDA: Zostavax).
Host Response

Human Response

  • Side Effects: The most common side effects reported included headache and injection site reactions (FDA: Zostavax).
  • Efficacy: According to clinical studies, ZOSTAVAX significantly reduced the risk of developing zoster when compared with placebo. Vaccine efficacy for the prevention of herpes-zoster (HZ) was highest for those subjects 60-69
    years of age and declined with increasing age (FDA: Zostavax).
References
FDA: Zostavax: FDA: Zostavax vaccine information [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094075.htm]